| Literature DB >> 25545762 |
Nerea Barrado Solís1, Paula Molés Poveda, César Lloret Ruiz, Virginia Pont Sanjuan, Manel Velasco Pastor, Esther Quecedo Estébanez, Javier Miquel Miquel.
Abstract
Actinic cheilitis (AC) are premalignant lesions that have an increased risk of malignant transformation. Their treatment, therefore, is essential to prevent carcinogenesis. However, optimal therapy is not well established and different modalities yield variable results. Ingenol mebutate gel has recently been approved by the US Food and Drug Administration for topical treatment of actinic keratosis, with high clearance rates. On the basis of these findings, we report our experience with this drug for the treatment of AC.Entities:
Keywords: actinic cheilitis; field-directed therapy; ingenol mebutate gel
Mesh:
Substances:
Year: 2014 PMID: 25545762 DOI: 10.1111/dth.12188
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851